RE: RE: RE: 18to20 Why would you get off of a horse when you are 100 feet from the finish line? It doesn’t make sense, and it doesn’t add up. Again, the timing of this takeover attempt seems very suspicious and appears very self serving to me. I have been involved with other highly promising companies that were taken over just short of fruition and the shareholders tend to wind up with ten cents on the dollar received for the inherent value of the established company. If Bioniche can’t deliver value over the next 6 months or 1 year, then I would be all for a takeover to happen at that time.
I never suggested waiting with the current management for more then another 6 months to a year without seeing positive headway on all fronts. They have already been most severely put on notice in that the pending turnaround must happen soon. There is a tremendous amount of value in the nearly validated vaccine plant, MCC platform, Urocidin, Oncocidin, Sin Susto, Immunocidin and Econiche going forward, as well as all of Bioniche’s established animal health products. It would certainly be only prudent to see if Bioniche can deliver in the short term with all the hard legwork already completed in getting us positioned for this success.
Mark my words, you will see this company bought out or sold off in parts and receive perhaps fifty cents or, if lucky, a dollar per share instead of many times that return if Bioniche delivers on the near term completion of their current endeavors. You sound happy with that return, and I am not. It is as simple as that. I agree to disagree. You would also be taking the risk that a takeover may backfire and actually decrease the value of Bioniche due to lack of understanding of the Bioniche business platform.